الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 183 |  |  |
| | | from | 183 | | |
Abstract
Colorectal cancer (CRC) or colon cancer, is one of the most common forms of cancer among Western people, where estimation of age-standardized rate (ASRs) by Globocan, 2020, [1]. In Egypt, it was reported previously that females appeared to be at a slightly higher risk of developing colon cancer with a prevalence of 1.2:1; [2, 3]. This situation is currently still the case where females have higher incidence and mortality ASRs of colon cancer than males [2]. Despite recent progress, colon cancer remains the third greatest cause of death among cancer patients worldwide (after lung and female breast cancers) [1].
Chemotherapy has great potential for treating cancer patients, but it has a lot of negative side effects on normal tissues [4]. Cetuximab is a chimeric monoclonal antibody that targets epidermal growth factor receptors (EGFR) by promoting EGFR internalization, blocking their natural ligands competitively, and changing EGFR-dependent signaling in some FDA-approved indications, such as metastatic colorectal cancer with wild-type KRAS (without mutation), and head and neck cancer (squamous cell). This study aims to fabricate optimal nanoparticles as carriers that can overcome the drawbacks of cetuximab to be used later in cancer therapy while the FDA‟s unapproved uses for cetuximab mainly include colorectal cancer with KRAS mutations, non-small cell lung cancer (NSCLC), EGFR expression, and advanced squamous cell skin cancer, with it having several side effects attributed to its interaction with normal cells, which interaction causes papulopustular rashes (acne-like), whereas fissures, eczema, and xerosis, telangiectasia, hyperpigmentation, and less frequently do nail and hair changes take place.